Chicago Consortium Women's Interagency HIV Study lll

描述(由申请人提供)作为一项多中心的前瞻性队列研究妇女机构间艾滋病毒研究(WIHS)旨在直接解决与妇女艾滋病毒的自然病史和临床表现有关的关键假设。在WIHS-III(12/02-11/07)期间，WIHS的科学目标是：1)开发、改进和评估暴露于抗逆转录病毒疗法(ART)的综合措施，并将这些措施与艾滋病毒疾病进展的标志联系起来；2)确定HIV-1感染的治疗历史和包括宿主和病毒遗传因素在内的对高效抗逆转录病毒疗法(HAART)的临床、病毒学和免疫学反应的个人决定因素；3)评估与ART相关的不良事件；4)调查HIV的长期影响和HMRT的使用；关于在感染艾滋病毒或感染艾滋病毒的妇女中引起疾病的病毒混合感染的发病率/自然病史，重点是人类乳头瘤病毒感染和宫颈肿瘤，以及丙型肝炎病毒感染和肝病，5)评估年龄、排卵功能、绝经及其治疗对艾滋病毒感染过程和抗逆转录病毒治疗的影响，6)描述妇女艾滋病毒相关癌症的流行病学，并进一步确定HAART治疗中女性恶性肿瘤的自然病史，以及7)评估艾滋病毒疾病的口腔表现。 芝加哥WIHS将利用其九年的成功保留战略，在四个临床地点吸引和留住390名参与者(295名HIV+，95名HIV-)，其中包括口腔站点的150名参与者，为期6个月的访问周期。这些将包括面谈、检查、血液、妇科和口腔样本、病历摘要、登记匹配以及本地和集中的实验室分析。 芝加哥WIHS将提供最高质量的数据，领导和参与流行病学分析，并传播从这项研究倡议中学到的结果和科学信息。作为我们特定地点的科学倡议，我们将研究HMRT中HIV感染女性的免疫恢复，特别是年龄、药物使用、外源性激素和更年期对免疫恢复的影响。

DESCRIPTION (provided by applicant) As a multicenter, prospective cohort study The Women's Interagency HIV Study (WIHS) is designed to directly address key hypotheses related to the natural history and clinical manifestation of HIV among women. During WIHS-III (12/02-11/07), WIHS scientific Aims are to 1) develop, refine, and evaluate composite measures of antiretroviral therapy (ART) exposure and relate these measures to markers of HIV disease progression, 2) define the treated history of HIV-1 infection and the individual determinants, including host and viral genetic factors, of clinical, virologic and immunologic response to highly-active antiretroviral therapy (HAART), 3) evaluate adverse events associated with ART, 4) investigate the long term effects of HIV, and use of HMRT, on the incidence/natural history of viral co-infections that cause disease in women with or at risk for HIV, focusing on human papillomavirus infection and cervical neoplasia, and hepatitis C virus infection and liver disease, 5) evaluate the effects of age, ovulatory function, menopause and its treatment on the course of HIV infection and response to ART, 6) describe the epidemiology of HIV- associated cancers in women, and further define the natural history of malignancies in women on HAART , and 7) evaluate the oral manifestations of HIV disease. Chicago WIHS will use its nine years of successful retention strategies to engage and retain 390 participants (295 HIV+, 95 HIV-) at four clinical sites including150 participants at the oral site through six month visit cycles. These will include interviews, exams, blood, gynecologic and oral specimens, medical record abstractions, registry matches, and local and centralized laboratory analysis. Chicago WIHS will contribute the highest quality data, lead and participate in epidemiologic analyses, and disseminate the results and scientific information learned from this research initiative. As our site-specific scientific initiative, we will investigate immune recovery in HIV infected women on HMRT with particular interest in the effects of age, drug use, exogenous hormones and menopause on immune recovery.